Phaseline

Companies › Nanjing King-Friend Biochemical Pharmaceutical

Nanjing King-Friend Biochemical Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NKF-PEG
Pegfilgrastim biosimilar; granulocyte colony-stimulating factor (G-CSF) analog
CSF3RPhase 1Healthy ParticipantsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07738991NKF-PEGPhase 1Healthy ParticipantsOtherNov 2026

From the company's SEC filings

Complete response letters from FDA

Targets

CSF3R (1)

Companies with the same targets

CSL Behring Savara Spectrum Pharmaceuticals Qilu Pharmaceutical Kexing Biopharm Yaqrit

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.